Results 11 to 20 of about 70,065 (194)

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. [PDF]

open access: yes, 2007
BACKGROUND: The safety of drug-eluting stents has been called into question by recent reports of increased stent thrombosis, myocardial infarction, and death.
Kirtane, Ajay J   +14 more
core   +1 more source

Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction [PDF]

open access: yes, 2002
Quantification of the new immunosuppressant sirolimus (syn. rapamycin; Rapamune((R))) in whole blood by chromatography is essential for its clinical use since no immunoassay is available although monitoring is mandatory.
Fleischer, Claudia   +5 more
core   +1 more source

Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells [PDF]

open access: yes, 2012
End Stage Renal Disease (ESRD) is an ever increasing problem worldwide. However the mechanisms underlying disease progression are not fully elucidated. This work addressed the nephrotoxicity induced by the immunosuppressive agents’ cyclosporine A (CsA ...
Ryan, Michael P.   +7 more
core   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. [PDF]

open access: yesPharmacotherapy
ABSTRACT Background Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute
Stojanova J   +9 more
europepmc   +2 more sources

Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series. [PDF]

open access: yesCancer Rep (Hoboken)
ABSTRACT Background This retrospective series reports outcomes and prognostic factors for advanced chordoma (AC) treatment with molecular targeted therapies (MTTs) in different treatment lines. Methods This is a retrospective series of 57 patients with AC treated between 2004 and 2023 at one of seven participating sarcoma centres.
Lipplaa A   +10 more
europepmc   +2 more sources

Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma. [PDF]

open access: yes, 2020
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor in children, which can be accompanied by life-threatening thrombocytopenia, referred to as Kasabach-Merritt phenomenon (KMP).
Richard Brill   +57 more
core   +1 more source

Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial [PDF]

open access: yes, 2012
A large prospective, open-label, randomized trial evaluated conversion from calcineurin inhibitor (CNI)- to sirolimus (SRL)-based immunosuppression for preservation of renal function in liver transplantation patients.
Barroso, E.   +61 more
core   +1 more source

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

open access: yes, 2010
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure ...
Pinna, Antonio D.   +392 more
core   +1 more source

Home - About - Disclaimer - Privacy